title: Pharmacokinetic study of icariside II after a single dose administration of YiGu capsule in healthy Chinese volunteers.
abstract: To investigate the pharmacokinetic characteristics of icariside II after a single oral dose administration of YiGu Capsule in healthy -Chinese volunteers. 8 (4 female) healthy Chinese volunteers were involved and administrated for 15 doses of YiGu Capsule after fasting overnight. 4 ml of blood samples were collected at scheduled time before and after administration. Icariside II in human plasma was separated on a Agela Venusil XBP-C18 column (250 mm×4.6 mm, 5 μm), and eluted using acetonitrile-water (containing 0.1% formic acid) (70:30, V/V) as mobile phase. The analytes were detected with a -triple quad HPLC-MS/MS using ESI with positive ionization. Ions monitored in the multiple reaction monitoring mode were m/z 515.1 (precursor ion) to m/z 369.1 (product ion) for icariside II and m/z 321.0 (precursor ion) to m/z 275.0 (product ion) for lorazepam (internal standard).The plasma concentration of icariside II was determined by established HPLC-MS/MS method after disposition and its pharmacokinetic parameters were analyzed and evaluated by PK Solver Software (version 1.0). The Cmax, Tmax, t1/2, AUC0-24, AUC0-∞, MRT0-∞-1, 2.50±1.91 h, 7.61±2.81 h, 12.68±4.86 ng · mL-1 · h, 14.22±5.75 ng · mL-1 · h, 9.55±1.56 h, 12.81±7.94 L · h-1 and 121.70±32.70 L. The established HPLC-MS/MS method was sensitive, selective and rapid for icariside II pharmacokinetic study.
authors.affiliation: Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan, Shandong, People's Republic of China.
authors.forename: X-y
authors.initials: XY
authors.lastname: Liu
authors.forename: C-m
authors.initials: CM
authors.lastname: Wei
authors.forename: R
authors.initials: R
authors.lastname: Zhang
authors.forename: G-y
authors.initials: GY
authors.lastname: Yuan
authors.forename: R-c
authors.initials: RC
authors.lastname: Guo
mesh_terms: D000328:Adult; D002214:Capsules; D002851:Chromatography, High Pressure Liquid; D004355:Drug Stability; D004365:Drugs, Chinese Herbal / Q000493:pharmacokinetics*; D005260:Female; D005419:Flavonoids / Q000737:chemistry / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D053719:Tandem Mass Spectrometry
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; D005419:Flavonoids; C060988:baohuoside I